| Autor: |
Wada H; Department of Laboratory Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. wadahide@clin.medic.mie-u.ac.jp, Sakakura M, Kushiya F, Nisikawa M, Onishi K, Nakatani K, Shiku H, Nobori T |
| Jazyk: |
angličtina |
| Zdroj: |
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2005 Jan; Vol. 16 (1), pp. 17-24. |
| DOI: |
10.1097/00001721-200501000-00003 |
| Abstrakt: |
Thrombomodulin (TM) has been under development as a medicine for disseminated intravascular coagulation (DIC), and is expected to exhibit strong anticoagulant activity by inhibiting thrombin generation via the acceleration of protein C activation. In the present study, we examined the pharmacological action of TM in plasma obtained from DIC patients. TM was found to inhibit thrombin generation and accelerate activated protein C (APC) production at 0.3-30 TM units/ml in plasma obtained from DIC patients irrespective of their underlying disorders. In addition, there was a positive correlation between the inhibition of thrombin generation and the amount of APC produced. Thrombin generation was inhibited by over 50% when the plasma level of APC was increased by more than 0.2 microg/ml. These results indicate that TM inhibits thrombin generation in plasma obtained from DIC patients by accelerating APC production. Moreover, the results imply that the thrombin generation test may be a good method to speculate the efficacy of TM on every patient before the administration of TM. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
